Article
Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.
Leukemia - 1 Mar 2018
Andersson E I, Pützer S, Yadav B, Dufva O, Khan S, He L, Sellner L, Schrader A, Crispatzu G, Oleś M, Zhang H, Adnan-Awad S, Lagström S, Bellanger D, Mpindi J P, Eldfors S, Pemovska T, Pietarinen P, Lauhio A, Tomska K, Cuesta-Mateos C, Faber E, Koschmieder S, Brümmendorf T H, Kytölä S, Savolainen E-R, Siitonen T, Ellonen P, Kallioniemi O, Wennerberg K, Ding W, Stern M-H, Huber W, Anders S, Tang J, Aittokallio T, Zenz T, Herling M, Mustjoki S
Abstract excerpt
T-cell prolymphocytic leukemia (T-PLL) is a rare and aggressive neoplasm of mature T-cells with an urgent need for rationally designed therapies to address its notoriously chemo-refractory behavior. The median survival of T-PLL patients is <2 years and clinical trials are difficult to execute. Here we systematically explored the diversity of drug responses in T-PLL patient samples using an ex vivo drug...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.